SPOTLIGHT: L'Oreal selling off chunk of Sanofi stock

L'Oreal is cutting its stake in Sanofi-Aventis by 1.8 percent by selling off shares through sales to institutional investors; the company will retain am 8.7 percent share in the drug maker. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.